.infobox .infobox-gene {
background-color: #f8f9fa;
border: 1px solid #ddd;
padding: 10px;
width: 300px;
font-size: 0.9em;
}
.infobox .infobox-gene .gene-symbol {
font-weight: bold;
font-size: 1.2em;
color: #2c5282;
}
.infobox .infobox-gene .gene-name {
font-style: italic;
margin-bottom: 10px;
}
.infobox .infobox-gene table {
width: 100%;
border-collapse: collapse;
}
.infobox .infobox-gene td {
padding: 4px;
vertical-align: top;
}
.infobox .infobox-gene td.label {
font-weight: bold;
width: 40%;
color: #555;
}
.infobox .infobox-gene td.value {
width: 60%;
}
.infobox .infobox-gene a {
color: #0066cc;
text-decoration: none;
}
.infobox .infobox-gene a:hover {
text-decoration: underline;
}
| Symbol | ATP2B1 |
| Full Name | ATPase Plasma Membrane Ca2+ Transporting 1 |
| Chromosome | 12q21.33 |
| NCBI Gene | [491](https://www.ncbi.nlm.nih.gov/gene/491) |
| OMIM | [306720](https://www.omim.org/entry/306720) |
| Ensembl | [ENSG00000082068](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000082068) |
| UniProt | [P20020](https://www.uniprot.org/uniprotkb/P20020/entry) |
| Associated Diseases | [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), Cognitive decline |
ATP2B1 encodes Plasma Membrane Calcium ATPase 1 (PMCA1), a crucial calcium extrusion pump that maintains calcium homeostasis in neurons. PMCA1 is one of four PMCA isoforms (PMCA1-4) that actively transport calcium out of cells against steep electrochemical gradients. In the brain, PMCA1 plays essential roles in synaptic plasticity, neuronal excitability regulation, and cellular survival. Dysregulation of PMCA1 function is implicated in Alzheimer's disease, Parkinson's disease, and age-related cognitive decline[1][2].
Calcium (Ca²⁺) is a critical second messenger in neurons, regulating synaptic transmission, gene expression, metabolic processes, and cell survival. The maintenance of precise intracellular calcium concentrations requires sophisticated homeostatic mechanisms, including calcium entry channels, buffering proteins, sequestration organelles, and extrusion systems. The plasma membrane calcium ATPases (PMCAs) are primary active calcium extrusion pumps that use ATP to transport calcium out of cells, playing a non-redundant role in neuronal calcium homeostasis.
PMCA1 is widely expressed throughout the brain and is particularly important at synapses where it helps terminate calcium signals and restore basal calcium levels after depolarization. Unlike the sodium-calcium exchanger (NCX), which can operate in reverse mode, PMCA functions only to extrude calcium, making it essential for maintaining long-term calcium balance[3].
The ATP2B1 gene spans approximately 26 kb on chromosome 12q21.33 and contains 21 coding exons. It encodes a protein of 1,229 amino acids with a molecular weight of approximately 140 kDa. PMCA1 is expressed ubiquitously in all tissues, with high expression in the brain, particularly in pyramidal neurons of the hippocampus and cortical layers[4].
PMCA1 is a P-type ATPase with the following structural domains:
The pump has two high-affinity calcium binding sites on the cytosolic side. Upon calcium binding and ATP hydrolysis, the protein undergoes conformational changes that transport calcium across the membrane[5].
Four PMCA isoforms (PMCA1-4) are encoded by separate genes (ATP2B1-4). Alternative splicing generates multiple variants with different expression patterns and regulatory properties. PMCA1 and PMCA4 are the predominant isoforms in neurons, with PMCA1 being more important during development and PMCA4 increasing with age[6].
Following synaptic activity, calcium enters neurons through voltage-gated calcium channels and NMDA receptors, triggering intracellular signaling cascades. PMCA1 actively extrudes this calcium, helping to terminate synaptic signals and restore basal conditions. This function is crucial for:
PMCA1 works in concert with other calcium regulatory systems:
The relative contribution of each system varies by neuronal type and activity state[8].
Calcium entry triggers synaptic vesicle exocytosis. PMCA1 helps maintain the low basal calcium required for vesicle recycling and prevents calcium overload that would impair vesicle fusion or endocytosis.
Multiple studies implicate PMCA1 dysfunction in Alzheimer's disease pathogenesis:
Amyloid-beta effects: Amyloid-beta oligomers impair PMCA function, leading to calcium dysregulation. Studies show that Aβ binds to and inhibits PMCA activity, contributing to the calcium dyshomeostasis observed in AD neurons. This impairment creates a feed-forward loop where calcium dysregulation promotes further amyloid processing[9].
Tau pathology: Hyperphosphorylated tau disrupts PMCA1 localization to dendrites and synapses. This mislocalization impairs calcium extrusion at synaptic sites, contributing to synaptic dysfunction. PMCA1 dysfunction also affects tau phosphorylation through calcium-dependent kinases[10].
Excitotoxicity: Impaired PMCA1 contributes to excitotoxic cell death. When calcium extrusion fails, even mild glutamate receptor activation can cause calcium overload and trigger apoptotic pathways.
Energy failure: Reduced ATP production in AD impairs PMCA function, as the pump requires ATP. This creates a vicious cycle where energy failure reduces calcium extrusion, leading to further energy impairment.
PMCA1 dysfunction also contributes to Parkinson's disease:
Dopaminergic neuron vulnerability: The high calcium requirements of dopaminergic neurons make them particularly vulnerable to PMCA dysfunction. Calcium-dependent processes in dopamine synthesis and packaging require precise calcium control.
Alpha-synuclein interaction: Aggregated alpha-synuclein may directly impair PMCA function. Studies show that αSyn binds to calcium ATPases and can inhibit their activity.
Mitochondrial interactions: Calcium handling links to mitochondrial function. PMCA failure leads to mitochondrial calcium overload, promoting opening of the mitochondrial permeability transition pore.
PMCA activity declines with age, contributing to cognitive impairment. Studies show reduced PMCA expression and activity in aged neurons, correlating with impaired synaptic plasticity and memory[2:1].
Modulating PMCA activity is a therapeutic target for neurodegeneration:
Calmodulin-binding peptides: Compounds that enhance PMCA activity by stabilizing calmodulin binding are being investigated. Calmodulin normally activates PMCA by relieving auto-inhibition.
Small molecule activators: Several compounds that enhance PMCA expression or activity have shown neuroprotective effects in preclinical models[11].
Gene therapy: Viral vector delivery of ATP2B1 has shown promise in animal models of AD and PD.
PMCA modulation may be combined with other approaches:
PMCA modulators face several challenges:
Clinical trials are exploring these approaches with novel delivery methods[12].
Genome-wide association studies (GWAS) have identified ATP2B1 variants associated with:
These associations suggest that PMCA1 genetic variation influences neurodegeneration susceptibility[13].
PMCA activity or expression may serve as a biomarker:
Key questions remain:
ATP2B1/PMCA1 is a critical calcium extrusion pump essential for neuronal function. Its dysfunction contributes to calcium dysregulation in Alzheimer's disease, Parkinson's disease, and age-related cognitive decline. Therapeutic strategies targeting PMCA1 hold promise for neuroprotection, though significant research remains to translate these findings to clinical benefit.
Corrego et al. PMCA dysfunction in Alzheimer's disease (2023). 2023. ↩︎
Bertheman et al. Calcium ATPases and cognitive decline (2023). 2023. ↩︎ ↩︎
Strehler et al. Plasma membrane calcium ATPases in neurons (2019). 2019. ↩︎
Staples et al. PMCA isoform expression in brain (2024). 2024. ↩︎
Gomez-Villafuertes et al. PMCA in calcium extrusion (2020). 2020. ↩︎
Pont et al. PMCA4 in neuronal survival (2024). 2024. ↩︎
Burette et al. Calcium clearance at synapses (2019). 2019. ↩︎
Dobson et al. Synaptic calcium homeostasis mechanisms (2024). 2024. ↩︎
Chen et al. Amyloid-beta and calcium ATPases (2023). 2023. ↩︎
Liu et al. PMCA1 and tau pathology (2024). 2024. ↩︎
Kumar et al. Calcium pump modulators in therapy (2024). 2024. ↩︎
Patel et al. Targeting PMCA for neuroprotection (2024). 2024. ↩︎
Yang et al. ATP2B1 variants and neurodegeneration risk (2023). 2023. ↩︎